Thermo Fisher Scientific plans to acquire allergy- and autoimmunity-diagnostics company Phadia from private equity firm Cinven for €2.47 billion ($3.5 billion), Thermo said this week.

The acquisition, expected to close in the fourth quarter, will expand Thermo Fisher's specialty-diagnostic business. During a conference call discussing the deal, CEO Marc Casper said the buy would increase the division's annual revenues to roughly $1.9 billion from around $1.4 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.